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diagnosed in 2000-2003 vs 2008-2010 (for HAART initiation: 62.5% vs 78.2%, 
P<0.01; for VS: 53.4% vs 70.7%, P<0.01, respectively), age <30 vs ≥40 years (57.6% 
vs 71.8%, P = 0.01 and 50.6% vs 66.3%, P<0.01), or non-Hispanic blacks (NHB) 
compared with non-Hispanic whites (NHW) (63.4% vs 67.1%, P = 0.01 and 56.2% 
vs 62.4%, P = 0.01). In multivariable models, patients were more likely to initiate 
HAART sooner if diagnosed after 2000-2003 (adjusted hazard ratios [95% 
confidence intervals] for 2004-2007 and 2008-2010: 1.2 [1.0-1.3] and 1.6 [1.3-1.9]) 
but were less likely to start if age <30 vs ≥40 years (0.8 [0.7-0.9]), NHB vs NHW (0.7 
[0.6-0.9]) and female (0.8 [0.7-1.0]). Similar findings were observed for achieving 
VS after diagnosis with the exception of sex. In an analysis of outcomes after 
HAART initiation, further adjusted for CD4 count and plasma HIV RNA viral load 
(VL) at HAART initiation, NHB compared with NHW were less likely to achieve VS 
after HAART initiation (0.7 [0.6-0.9]), while age and gender were no longer 
significant explanatory factors. CONCLUSIONS: During 2000-2010, starting 
HAART and achieving VS ≤12 months became increasingly more common. 
Adjusting for CD4 and VL at start of HAART, only NHB had decreased likelihood 
of achieving VS after HAART initiation.  
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OBJECTIVES: This study examined the influenza vaccination rates and racial and 
ethnic disparities in receiving influenza vaccinations within the past year among 
community pharmacy users and individuals who did not utilize community 
pharmacies. METHODS: The 2009 Medical Expenditure Panel Survey was 
analyzed. The sample consisted of respondents aged 50 years or older, as per the 
2009 recommendations by the Advisory Committee on Immunization Practices. 
Bivariate analyses and multivariate logistic regression were conducted to 
examine the influenza vaccination rates and disparities in the likelihood of 
receiving influenza vaccinations within past year between non-Hispanic Whites 
(Whites), non-Hispanic Blacks (Blacks) and Hispanics. The influenza vaccination 
rates and the likelihood of receiving influenza vaccinations between community 
pharmacy users and non-users were also examined. RESULTS: The sample 
consisted of 71,135,249 (weighted) community pharmacy users and 20,565,253 
(weighted) non-users. Bivariate analyses found that a greater proportion of 
Whites received influenza vaccinations compared to Blacks and Hispanics, 
among both the community pharmacy users (60.1% vs. 49.1% and 51.7%, 
respectively; P<0.0001) and non-users (41.0% vs. 24.3% and 26.0%, respectively; 
P<0.0001). Adjusted logistic regression analyses found significant racial 
disparities between Blacks and Whites; compared to Whites, Blacks were found 
to have a 19 percent lower likelihood among community pharmacy users (odds 
ratio [OR]: 0.81; 95% CI: 0.69-0.95), and a 34 percent lower likelihood among non-
users (OR: 0.66; 95% CI: 0.46-0.94), respectively, of receiving influenza 
vaccinations. Sociodemographic characteristics and health status accounted for 
the disparities between Hispanics and Whites. Overall, community pharmacy 
users had higher influenza vaccination rates (P<0.0001) and were more likely to 
receive influenza vaccinations compared to non-users (P<0.05). CONCLUSIONS: 
Despite influenza vaccination rates being higher among community pharmacy 
users, there were racial disparities in receiving influenza vaccinations among 
both community pharmacy users and non-users. Increased emphasis on 
educational and awareness campaigns among pharmacists and pharmacy 
patrons is needed.  
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Gerritzen BC 
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OBJECTIVES: Gender inequality has been identified as a key driver of the HIV 
epidemic by UN AIDS; understanding the gendered nature of the HIV epidemic is 
thus of high policy-relevance. Condom use and communication among sexual 
partners are important strategies for HIV prevention. Previous research on the 
impact of women’s empowerment on the uptake of HIV prevention has either 
focused on economic empowerment only or has left unresolved issues with 
respect to unobserved heterogeneity. METHODS: Using a panel data set of more 
than 1,200 married women in rural Malawi from 1998-2008, this paper shows 
that adequate HIV prevention strategies, i.e. condom use within marriage and 
HIV-related spousal communication, are more widely used as women's 
bargaining power increases. I focus on different dimensions of women’s 
empowerment, namely personal (e.g. education and economic empowerment) 
and interpersonal empowerment (e.g. social status and outside options). 
RESULTS: Among the proxies used for women's empowerment, own income, 
knowledge of other local languages and awareness of exit options from marriage 
are found to play a particularly important role in promoting adequate preventive 
behaviors. The main findings continue to hold after individual-specific fixed 
effects and time dummies are included in order to account for unobserved 
heterogeneity and time trends. CONCLUSIONS: The importance of women’s 
empowerment in fighting the spread of HIV is rarely disputed, yet many 
HIV/AIDS campaigns fail to tackle underlying gender inequalities. The results 
from my analysis suggest that greater emphasis should be placed on women’s 
empowerment in order to effectively combat the spread of the HIV/AIDS 
epidemic, particularly in developing countries.  
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OBJECTIVES: Estimate vaccine coverage with hepatitis B birth dose in children 
under 10 years old in high endemic areas of Colombia. Describe how children are 
vaccinated against Hepatitis B in high endemic areas that are hard to reach due 
to geographical barriers. Evaluate factors associated with adequate vaccination 
of newborns with the Hepatitis B birth dose. METHODS: A cross sectional study 
is being carried out in rural areas of the Colombian Amazon. Vaccination history 
was recorded for 953 children < 10yrs who had a vaccine card. Data were 
recollected in three areas of the Colombian Amazon: Leticia, Puerto Nariño and 
Tarapaca.. Children were considered to have a birth dose if they were vaccinated 
with the monovalent vaccine in the first seven days after delivery. Logistic 
models were used to estimate association of valid vaccination with several 
variables. RESULTS: A total of 79.9% of the children received a birth dose of 
hepatitis B, 38.4% received the vaccine in the first week after delivery; 30.9% 
were vaccinated in the first day and 7.6% in the next seven days. Bivariate 
analysis: Birth dose was associated (p<0.00) to children delivered at a health 
facility, health professional assisting the delivery, children living in households 
with at least one of the following (TV, radio, refrigerator or a boat), children born 
to women with a higher education level. Multivariate analysis: Only delivering at 
a health facility was associated with receiving of the birth dose (OR 26.9 CI 95% 
17.8-40.7) CONCLUSIONS: Our study shows children in rural areas are 
inadequately vaccinated even though they live in a high risk area for hepatitis B 
infection and vertical transmission of the HVB is common. Because all children 
cannot be delivered at a hospital due to geographical barriers new strategies 
need to be studied to vaccinate newborns in the rural areas.  
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OBJECTIVES: To estimate the financial impact of currently uninsured individuals 
infected with chronic hepatitis C (CHC) who will enter the health care system in 
2014 under the Affordable Care Act. METHODS: Uninsured CHC prevalence 
estimates among the US household population were obtained by aggregating 
data from three National Health and Nutrition Examination Surveys (NHANES) 
conducted between 2005 and 2010. Commercial insurance claims data from 2007 
to 2011 were used to estimate the average annualized all-cause direct medical 
cost of a CHC patient. ICD-9 diagnosis codes were used to identify CHC patients. 
All medical service and prescription pharmacy costs were tracked longitudinally 
and subsequently adjusted for inflation and length of enrollment. RESULTS: The 
prevalence rate of CHC among the US household population was 0.89% during 
2005-2010 (95% CI (0.69%, 1.09%)). A total of 40.12% of these individuals were 
uninsured (95% CI (32.02%, 48.21%)). Applying NHANES prevalence rates to US 
Census Bureau’s current population survey data, the estimated 2011 uninsured 
CHC population was 1.1MM. However, only 25% or 275,000 individuals may be 
diagnosed. The average annual medical cost for privately insured diagnosed CHC 
patients was approximately $24,000. Combining the uninsured CHC prevalence 
and cost estimates, the annual direct cost of these currently uninsured 
diagnosed CHC individuals is approximately $6.6B when they enter the health 
system. The overall incremental cost of currently uninsured CHC individuals 
may be even higher due to the cost incurred by the undiagnosed CHC population. 
CONCLUSIONS: A large proportion of CHC infected individuals are currently 
uninsured. When the ACA health insurance mandate takes effect in 2014, this 
population will gain access to health care coverage and could substantially 
increase the cost to the health care system.  
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OBJECTIVES: Several randomized studies confirmed the efficacy and safety of 
peginterferon-based antiviral therapy for patients with hepatitis C virus 
infection. However, various types of patients who were not included in those 
studies are possibly seeking antiviral therapy in daily practice. The study aim 
was to analyze those patients and their treatment situation in a real-world 
setting. METHODS: A large claims database (Medical Data Vision, Japan; 4/2010 - 
6/2012) was retrospectively analyzed. The study patients were those who had 
evidence of CHC (ICD10: B182) and initiated either the combination therapy with 
peginterferon + ribavirin (PR) or the triple therapy with peginterferon + ribavirin 
+ telaprevir (PR+T) from November, 2011. RESULTS: A total of 207 patients were 
identified, with 136 patients initiating PR (median age 56 years) and 71 patients 
initiating PR+T (median age 60 years). A quarter of patients were aged ≥65 in both 
therapy groups. 6% of patients given PR and 13% of patients given PR+T were 
previously diagnosed with hepatocellular carcinoma (HCC). Mean initial doses of 
peginterferon and ribavirin were similar between PR and PR+T however, mean 
adherence to the ribavirin dose in PR+T was 78% and lower than PR (95%). 
Patients requiring hospitalizations for treatment initiation were significantly 
different between PR and PR+T (71% vs. 93%, P<0.01); lengths of stay were 11.8 
and 18.5 days in PR and PR+T, respectively (P<0.01), P-values were not changed 
after adjusting for patient age, gender, and previous diagnosis of HCC and 
cirrhosis. CONCLUSIONS: The study found that a quarter of patients were elderly 
and the majority of patients required hospitalization to start treatment with 
either PR or PR+T. More effective and safer treatment is desirable. Further 
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research is needed to understand how differences in the characteristics of the 
patients treated with PR+T versus PR impact on treatment adherence and 
hospitalization patterns observed.  
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Durden E1, Maiese BA2, Foley K2 
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OBJECTIVES: To evaluate hepatitis A (HAV) endemicity in six countries via 
systematic review of published literature. The countries represent varying 
seroprevalence (different stages of the HAV epidemiologic transition), stages of 
vaccine consideration, and face different circumstances that may affect vaccine 
adoption. METHODS: Articles published from 1990 to October 2011 were 
identified through a number of article search engines, including PubMed®. Search 
terms were “Hepatitis A” and [Country]. Reference lists of identified articles were 
reviewed for relevant articles published prior to 1990. A supplementary Internet 
search identified additional information not indexed in the reviewed search 
engines. Articles were excluded if they focused on the biological mechanisms of 
hepatitis A, were non-human studies, vaccine trial results, case studies or 
opinion pieces. RESULTS: A total of 797 articles were identified. After exclusions, 
the number of articles reviewed were: Chile, 33; India, 80; Mexico, 25; Russia, 38; 
South Korea, 75; and Taiwan, 65. India is still considered to have high HAV 
endemicity, while Chile and Mexico are intermediate, and Korea, Russia, and 
Taiwan are low. The timeframe of available data differed greatly by country and 
often region/city within a country, with some regions only having data as recent 
as five (in Mexico, Taiwan) or ten (in Chile, India, Russia) years ago. Data 
supporting the HAV epidemiologic transition varied by country, and it was often 
unclear at which point the country transitioned to a lower endemicity category, 
if at all. Hepatitis A incidence data were sparse for some countries, and recent 
outbreaks were reported in Korea and Taiwan. CONCLUSIONS: Data gaps, 
including determination of the HAV epidemiologic transition, exist to some 
extent in all the countries studied. Filling these data gaps to enhance knowledge 
of the burden of HAV will assist countries in decision-making regarding vaccine 
adoption.  
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OBJECTIVES: Pharmaceutical spending in Brazil represents approximately 11% of 
its total Gross Domestic Product (GDP). Sales of generics represented 17.2% of the 
pharmacy sector by value and 21.3% by volume in 2010, and are expected to grow 
at a higher rate than the overall pharmacy market. This study looks at how the 
increase in generics use, along with reference price controls, may impact access 
to newly approved Community Acquired Pneumonia (CAP) drugs. METHODS: An 
array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a 
telephone survey of national and regional health care stakeholders (N=5). 
RESULTS: Findings show that in Brazil: 1) New CAP products are placed in 1 of 2 
product categories based on comparisons to comparator agents; 2) Category I 
products are considered to be better than the comparator and can charge a 
premium price; 3) The price cannot exceed the lowest price of 9 reference 
countries, which are Australia, Canada, Spain, USA, France, Greece, Italy, New 
Zealand and Portugal; 4) Category II products do not demonstrate a benefit over 
the comparator and the price is based on a cost-minimization analysis; and 5) 
There are no national guidelines for treating CAP. CONCLUSIONS: Drugs used to 
treat CAP are compared to comparator agents based on clinical efficacy and 
overall patient benefit. This will determine placement in a product category that 
will drive pricing. Pharmaceutical companies developing new antibiotics to treat 
CAP must 1) consider launch sequence/timing in reference price countries; 2) 
assess the impact of price based on product category placement; 3) demonstrate 
cost–effectiveness of the drug; and 4) determine whether a new product will 
provide a benefit over comparator agents.  
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Dean B1, Debes R2, Bozzette S3, Buchacz K4, Brooks JT4 
1Cerner Research, Culver City, CA, USA, 2Cerner Corporation, North Kansas City, MO, USA, 
3Cerner Research and the University of California, San Diego, Culver City, CA, USA, 4Centers for 
Disease Control and Prevention, Atlanta, GA, USA  
OBJECTIVES: Attendance at biannual medical visits has been proposed as a 
minimum U.S. standard for adequate engagement in human immunodeficiency 
virus (HIV) care. The U.S. National HIV Surveillance System collects dates of HIV 
laboratory tests but not medical visits, the current metric for determining if a 
patient is engaged in medical care. Using data from the HIV Outpatient Study 
(HOPS), we analyzed how reported laboratory data correlated with actual 
engagement in care. METHODS: The HOPS is an open prospective study of HIV-
infected patients receiving outpatient care. The dataset included dates for 
laboratory measurements and medical encounters. We included patients with at 
least one HIV laboratory test and one medical visit during 2010-2011. An HIV 
laboratory test was associated with a medical visit if it occurred within 3 weeks 
of the visit. We assessed the predictive value of HIV laboratory tests as a proxy 
for adequate engagement in clinical care, defined as having had ≥2 HIV 
laboratory tests within 1 year where the tests were performed ≥90 days apart. 
RESULTS: A total of 10,301 HIV laboratory tests were recorded from among 2,895 
patients. Most (75%) laboratory tests were measured on the same day as a 
clinical visit; 90% were within ±3 weeks. The prevalence of adequate engagement 
in clinical care in HOPS based on medical visits was 89%. Using HIV laboratory 
tests to measure engagement had sensitivity of 85%, specificity of 87%, and 
positive and negative predictive values of 98% and 42%. Of the 21.4% of persons 
classified as not engaged in care by the proxy measure, 58% were actually 
engaged. CONCLUSIONS: Using ≥2 documented HIV laboratory tests measured 
≥90 days apart reliably classified persons as engaged in care. However, more 
than half of persons not meeting the proxy definition were misclassified as not 
adequately engaged in care.  
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OBJECTIVES: Timely initiation of antifungal therapy in septic or critically ill 
(CrILL) patients with candidemia is crucial, and real-world treatment and 
outcomes data in such patients are limited. We examined treatment patterns 
and outcomes for septic/CrILL inpatients with candidemia. METHODS: This 
retrospective study of electronic health record data from 7/2005-3/2012 used 
Cerner’s Health Facts. Adult inpatients with ≥1 blood culture positive for any 
species of Candidaand sepsis/CrILL were studied. CrILL was defined as ≥1 organ 
system dysfunction plus intensive care unit exposure. Timing of initial 
antifungal therapy relative to the index blood culture draw (BCx), length-of-stay 
following first antifungal order (AF-LOS), mortality, and measures of resource 
utilization were explored using descriptive statistics. Chi-square was used for 
proportional, and t-test for continuous data comparisons. RESULTS: Of 1,288 
candidemia patients with sepsis/CrILL, 266 initiated antifungal therapy prior to 
BCx, 150 within 24h of BCx, 590 after 24h, and 282 received no antifungal 
therapy. The mortality rates were 39.9%, 30.7%, 29.7%, and 51.1%, respectively. 
(P<0.001). Initial antifungal therapies in those treated ≤24h of BCx were: 
fluconazole in 54.0%, echinocandin in 39.3%, other azoles in 3.3%, and 
amphotericin B in 3.3%. In patients treated within 24h after BCx with fluconazole 
(n=81) or echinocandin (n=59), occurrence of bacteremia was high (71% vs. 75%); 
echinocandin patients had a higher mean number of organ system dysfunctions 
than fluconazole patients (1.8 vs. 1.5, P=0.04). In the ≤24h treated groups, AF-LOS 
(fluconazole 20.8, echinocandin 22.1 days; P=0.63) and mortality (fluconazole 
25.9%, echinocandin 32.2%; P=0.42) was similar, as were total charges 
(approximately US$76,000). CONCLUSIONS: A large proportion of inpatients with 
candidemia and sepsis/CrILL failed to receive antifungal therapy within 24h of 
the first positive BCx, with an adverse mortality effect. Nonetheless, patients 
treated within 24h have high mortality and resource utilization.  
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OBJECTIVES: In clinical practice, the taste of liquid pediatric antibiotics may 
contribute to treatment acceptance and compliance. The purpose of this study 
was to analyze treatment patterns and persistence with liquid pediatric 
antibiotics, in a real life setting, using the RAMQ database. METHODS: Selected 
patients were < than 20 years old and were covered by the Quebec provincial 
drug reimbursement program (RAMQ). They were prescribed a liquid pediatric 
antibiotic (branded or generic formulation) during the period from July 2008 to 
April 2011 at least once. The analyses evaluated patients and treatment 
characteristics and patterns in terms of short-term (30 days or less) and long-
term (> than 30 days) repeated use. RESULTS: Data were available for a sample of 
67,727 patients who used an antibiotic of interest. The average age of the study 
population was 4.7 years (SD=3.5) and 89.9% were < than 10 years old. The 
proportion of boys versus girls was similar (51.2% versus 48.8%, respectively). 
Amoxicillin trihydrate and macrolides, clarithromycin and azithromycin were 
most often used (49.3% and 33.0%, respectively). About 55.4% of children received 
more than one antibiotic during the study period. Among children who received 
a second antibiotic, about 22.5% required it within 30 days following treatment 
initiation. In the short-term, the need for a second antibiotic was more frequent 
when cephalosporin was the initial treatment. In the long-term, when the initial 
treatment was amoxicillin or a macrolide, subsequent antibiotics were more 
likely to be the same as the first antibiotic. CONCLUSIONS: Many children will 
require more than one antibiotic treatment during their childhood. Several 
factors may contribute to short-term acceptance and compliance of the initial 
antibiotic, one of which may be taste. The better the acceptance and compliance 
to the initial antibiotic, the more likely the same antibiotic will be used for 
subsequent treatments.  
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COMPARATIVE RISKS OF SEVERE CUTANEOUS REACTIONS, ASEPTIC 
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